CLDN6 and ovarian carcinoma: Such findings nominate CLDN6 as both a prognostic biomarker and a potential therapeutic target for aggressive endometrial cancer (efforts to target CLDN6 with vaccines or CAR-T cells are underway in ovarian cancer, which could extend to endometrial cancer given CLDN6’s similar ectopic expression).